Related Experiment Videos
CDKN2 (MTS1/p16INK4A) gene alterations in hematological malignancies
T Uchida1, T Kinoshita, H Saito
1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Leukemia & Lymphoma
|February 1, 1997
Summary
The CDKN2 gene, a cell cycle regulator, acts as a tumor suppressor. Its alterations are frequent in lymphoid malignancies, suggesting its role in tumorigenesis.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Cyclin-dependent kinases (CDKs) complex with cyclins to regulate cell cycle progression.
- CDK inhibitors (CDKIs) arrest cell cycle progression; their functional loss is linked to tumorigenesis.
- The CDKN2 gene (MTS1/p16INK4A) on chromosome 9p21 encodes a CDKI, p16.
Purpose of the Study:
- To investigate the role of the CDKN2 gene in tumorigenesis, particularly in hematological malignancies.
- To identify the mechanisms of CDKN2 gene inactivation in various tumor types.
Main Methods:
- Analysis of CDKN2 gene alterations in tumor samples.
- Investigation of chromosomal abnormalities in the 9p21 region.
- Examination of homozygous deletions and point mutations in the CDKN2 gene.
Main Results:
- Alterations in the CDKN2 gene are frequent in various tumors, supporting its tumor suppressor function.
- CDKN2 gene alterations are observed in lymphoid malignancies, including T-cell acute lymphocytic leukemias, non-Hodgkin's lymphomas, and lymphoid blastic crisis.
- The primary mechanism of CDKN2 inactivation is homozygous deletion, with point mutations also contributing.
Conclusions:
- The CDKN2 gene is a major tumor suppressor gene on chromosome 9p21.
- CDKN2 gene inactivation is implicated in the tumorigenesis of diverse lymphoid malignancies.